Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACT: Anastrozole vs Anastrozole + Fulvestrant in Breast Cancer
NCT00256698Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2004
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of fulvestrant in breast cancer, sponsored by AstraZeneca. Primary endpoint: Time to Progression. Started Jan 2004; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00256698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256698.